The Correlation between Interleukin-18, Vascular Endothelial Growth Factor Expression and Clinicopathologic Parameters for Invasive Breast Cancer_West China Medical Journal

Authors：

LIU Xuejuan , ZHANG Qian ,  WANG Jing

Department of Thyroid and Breast Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding?author：

WANG Jing, Email: juanlx@126.com

Keywords：

乳腺癌; 白細胞介素18; 血管內皮生長因子; 表達

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的　通過檢測浸潤性乳腺癌中白細胞介素18（IL-18）和血管內皮生長因子（VEGF）的表達情況，探討其表達相關性及與臨床病理學參數的關系。方法　應用免疫組織化學法檢測IL-18和VEGF在42例浸潤性乳腺癌組織和12例正常乳腺組織中的表達情況。結果　IL-18和VEGF在42例浸潤性乳腺癌中的表達陽性率均顯著高于12例正常乳腺組織（P＜0.05）。且在42例浸潤性乳腺癌組織中，IL-18陽性組中VEGF陽性率（87.1%）顯著高于IL-18陰性組中VEGF陽性率（12.9%），差異有統計學意義（P＜0.05）。在亞組分析中，IL-18的表達只與有無腋窩淋巴結轉移有相關性（P＜0.05），而VEGF的表達與有無腋窩淋巴結轉移和TNM分期有相關性（P＜0.05）。結論　在浸潤性乳腺癌中，IL-18的表達上調與VEGF的表達上調顯著相關，IL-18可能具有促進腫瘤新生血管形成的作用。

Citation： LIU Xuejuan,ZHANG Qian,WANG Jing. The Correlation between Interleukin-18, Vascular Endothelial Growth Factor Expression and Clinicopathologic Parameters for Invasive Breast Cancer. West China Medical Journal, 2012, 27(10): 1458-1461. doi: Copy

1.	Kim KE, Song H, Kim TS, et al. Interleukin-18 is a critical factor for vascular endothelial growth factor-enhanced migration in human gastric cancer cell lines[J]. Oncogene, 2007, 26(10): 1468-1476.
2.	Kang JS, Bae SY, Kim HR, et al. Interleukin-18 increases metastasis and immune escape of stomach cancer via the downregulation of CD70 and maintenance of CD44[J]. Carcinogenesis, 2009, 30(12): 1987-1996.
3.	Nong SJ, Zhang YP, Zhou SJ, et al. Relationship between serum IL-18 and VEGF levels in patients with prostate cancer[J]. Chinese-German J Clin Oncol, 2010, 9(11): 643-647.
4.	Tsuboi K, Tatsuya M, Nakajima M, et al. Serum interleukin-12 and interleukin-18 levels as a tumor marker in patients with esophageal carcinoma[J]. Cancer Lett, 2004, 205(2): 207-214.
5.	Jebreel A, Mistry D, Loke D, et al. Investigation of interleukin 10, 12 and 18 levels in patients with head and neck cancer[J]. J Laryngol Otol, 2007, 121(3): 246-252.
6.	Park H, Byun D, Kim TS, et al. Enhanced IL-18 expression in common skin tumors[J]. Immunol Lett, 2001, 79(3): 215-219.
7.	Vidal-Vanaclocha F, Mendoza L, Telleria N, et al. Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression[J]. Cancer Metastasis Rev, 2006, 25(3): 417-434.
8.	Xia D, Zheng S, Zhang W, et al. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen[J]. J Mol Med, 2003, 81(9): 585-596.
9.	Okamura H, Tsutsui H, Kashiwamura S, et al. Interleukin-18: a novel cytokine that augments both innate and acquired immunity[J]. Adv Immunol, 1998, 70: 281-312.
10.	Marshall DJ, Rudnick KA, Mccarthy SG, et al. Interleukin-18 enhances Th1 immunity and tumor protection of a DNA vaccine[J]. Vaccine, 2006, 24(3): 244-253.
11.	Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF[J]. Science, 1999, 284(5422): 1994-1998.
12.	Asahara T, Kalka C, Isner JM, et al. Stem cell therapy and gene transfer for regeneration[J]. Gene Ther, 2000, 7(6): 451-457.
13.	Rafii S. Circulating endothelial precursors: mystery, reality, and promise[J]. J Clin Invest, 2000, 105(1): 17-19.
14.	Conti CJ. Vascular endothelial growth factor: regulation in the mouse skin carcinogenesis model and use in antiangiogenesis cancer therapy[J]. Oncologist, 2002, 7 Suppl 3(3): 4-11.
15.	Bandoh N, Hayashi T, Takahara M, et al. VEGF and bFGF expression and microvessel density of maxillary sinus squamous cell carcinoma in relation to p53 status, spontaneous apoptosis and prognosis[J]. Cancer Lett, 2004, 208(2): 215-225.
16.	Cho ML, Jung YO, Moon YM, et al. Interleukin-18 induces the production of vascular endothelial growth factor (VEGF) in rheumatoid arthritis synovial fibroblasts via AP-1-dependent pathways[J]. Immunol Lett, 2006, 103(2): 159-166.
17.	Amin MA, Rabquer BJ, Mansfield PJ, et al. Interleukin 18 induces angiogenesis in vitro and in vitro via Src and Jnk kinases[J]. Ann Rheum Dis, 2010, 69(12): 2204-2212.
18.	Grimm D, Bauer J, Ulbrich C, et al. Different responsiveness of endothelial cells to vascular endothelial growth factor and basic fibroblast growth factor added to culture media under gravity and simulated microgravity[J]. Tissue Eng Part A, 2010, 16(5): 1559-1573.
19.	Qiao H, Sonoda KH, Sassa Y, et al. Abnormal retinal vascular development in IL-18 knockout mice[J]. Lab Invest, 2004, 84(8): 973-980.
20.	Qiao H, Sonoda KH, Ikeda Y, et al. Interleukin-18 regulates pathological intraocular neovascularization[J]. J Leukoc Biol, 2007, 81(4): 1012-1021.
21.	Günel N, Co?kun U, Sancak B, et al. Clinical importance of serum interleukin-18 and nitric oxide activities in breast carcinoma patients[J]. Cancer, 2002, 95(3): 663-667.
22.	Crohns M, Saarelainen S, Laine S, et al. Cytokines in bronchoalveolar lavage fluid and serum of lung cancer patients during radiotherapy-association of interleukin-8 and VEGF with survival[J]. Cytokine, 2010, 50(1): 30-36.
23.	Coskun U, Gunel N, Sancak B, et al. Effect of tamoxifen on serum IL-18, vascular endothelial growth factor and nitric oxide activities in breast carcinoma patients[J]. Clin Exp Immunol, 2004, 137(3): 546-551.
24.	Merendino RA, Gangemi S, Ruello A, et al. Serum levels of interleukin-18 and sICAM-1 in patients affected by breast cancer: preliminary considerations[J]. Int J Biol Markers, 2001, 16(2): 126-129.
25.	Carbone A, Vizio B, Novarino A, et al. IL-18 paradox in pancreatic carcinoma: elevated serum levels of free IL-18 are correlated with poor survival[J]. J Immunother, 2009, 32(9): 920-931.

1. 　Kim KE, Song H, Kim TS, et al. Interleukin-18 is a critical factor for vascular endothelial growth factor-enhanced migration in human gastric cancer cell lines[J]. Oncogene, 2007, 26(10): 1468-1476.
2. 　Kang JS, Bae SY, Kim HR, et al. Interleukin-18 increases metastasis and immune escape of stomach cancer via the downregulation of CD70 and maintenance of CD44[J]. Carcinogenesis, 2009, 30(12): 1987-1996.
3. 　Nong SJ, Zhang YP, Zhou SJ, et al. Relationship between serum IL-18 and VEGF levels in patients with prostate cancer[J]. Chinese-German J Clin Oncol, 2010, 9(11): 643-647.
4. 　Tsuboi K, Tatsuya M, Nakajima M, et al. Serum interleukin-12 and interleukin-18 levels as a tumor marker in patients with esophageal carcinoma[J]. Cancer Lett, 2004, 205(2): 207-214.
5. 　Jebreel A, Mistry D, Loke D, et al. Investigation of interleukin 10, 12 and 18 levels in patients with head and neck cancer[J]. J Laryngol Otol, 2007, 121(3): 246-252.
6. 　Park H, Byun D, Kim TS, et al. Enhanced IL-18 expression in common skin tumors[J]. Immunol Lett, 2001, 79(3): 215-219.
7. 　Vidal-Vanaclocha F, Mendoza L, Telleria N, et al. Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression[J]. Cancer Metastasis Rev, 2006, 25(3): 417-434.
8. 　Xia D, Zheng S, Zhang W, et al. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen[J]. J Mol Med, 2003, 81(9): 585-596.
9. 　Okamura H, Tsutsui H, Kashiwamura S, et al. Interleukin-18: a novel cytokine that augments both innate and acquired immunity[J]. Adv Immunol, 1998, 70: 281-312.
10. 　Marshall DJ, Rudnick KA, Mccarthy SG, et al. Interleukin-18 enhances Th1 immunity and tumor protection of a DNA vaccine[J]. Vaccine, 2006, 24(3): 244-253.
11. 　Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF[J]. Science, 1999, 284(5422): 1994-1998.
12. 　Asahara T, Kalka C, Isner JM, et al. Stem cell therapy and gene transfer for regeneration[J]. Gene Ther, 2000, 7(6): 451-457.
13. 　Rafii S. Circulating endothelial precursors: mystery, reality, and promise[J]. J Clin Invest, 2000, 105(1): 17-19.
14. 　Conti CJ. Vascular endothelial growth factor: regulation in the mouse skin carcinogenesis model and use in antiangiogenesis cancer therapy[J]. Oncologist, 2002, 7 Suppl 3(3): 4-11.
15. 　Bandoh N, Hayashi T, Takahara M, et al. VEGF and bFGF expression and microvessel density of maxillary sinus squamous cell carcinoma in relation to p53 status, spontaneous apoptosis and prognosis[J]. Cancer Lett, 2004, 208(2): 215-225.
16. 　Cho ML, Jung YO, Moon YM, et al. Interleukin-18 induces the production of vascular endothelial growth factor (VEGF) in rheumatoid arthritis synovial fibroblasts via AP-1-dependent pathways[J]. Immunol Lett, 2006, 103(2): 159-166.
17. 　Amin MA, Rabquer BJ, Mansfield PJ, et al. Interleukin 18 induces angiogenesis in vitro and in vitro via Src and Jnk kinases[J]. Ann Rheum Dis, 2010, 69(12): 2204-2212.
18. 　Grimm D, Bauer J, Ulbrich C, et al. Different responsiveness of endothelial cells to vascular endothelial growth factor and basic fibroblast growth factor added to culture media under gravity and simulated microgravity[J]. Tissue Eng Part A, 2010, 16(5): 1559-1573.
19. 　Qiao H, Sonoda KH, Sassa Y, et al. Abnormal retinal vascular development in IL-18 knockout mice[J]. Lab Invest, 2004, 84(8): 973-980.
20. 　Qiao H, Sonoda KH, Ikeda Y, et al. Interleukin-18 regulates pathological intraocular neovascularization[J]. J Leukoc Biol, 2007, 81(4): 1012-1021.
21. 　Günel N, Co?kun U, Sancak B, et al. Clinical importance of serum interleukin-18 and nitric oxide activities in breast carcinoma patients[J]. Cancer, 2002, 95(3): 663-667.
22. 　Crohns M, Saarelainen S, Laine S, et al. Cytokines in bronchoalveolar lavage fluid and serum of lung cancer patients during radiotherapy-association of interleukin-8 and VEGF with survival[J]. Cytokine, 2010, 50(1): 30-36.
23. 　Coskun U, Gunel N, Sancak B, et al. Effect of tamoxifen on serum IL-18, vascular endothelial growth factor and nitric oxide activities in breast carcinoma patients[J]. Clin Exp Immunol, 2004, 137(3): 546-551.
24. 　Merendino RA, Gangemi S, Ruello A, et al. Serum levels of interleukin-18 and sICAM-1 in patients affected by breast cancer: preliminary considerations[J]. Int J Biol Markers, 2001, 16(2): 126-129.
25. 　Carbone A, Vizio B, Novarino A, et al. IL-18 paradox in pancreatic carcinoma: elevated serum levels of free IL-18 are correlated with poor survival[J]. J Immunother, 2009, 32(9): 920-931.

West China Medical Journal

The Correlation between Interleukin-18, Vascular Endothelial Growth Factor Expression and Clinicopathologic Parameters for Invasive Breast Cancer

Abstract Full text Figures/Tables Video References Cited by

Format

Content